Status:
UNKNOWN
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.
Detailed Description
The aim of this study is to include 40 patients with middle-advanced Hepatocellular Carcinoma .These patients were randomly allocated to TACE treatment group or TACE+Anlotinib treatment group.The trea...
Eligibility Criteria
Inclusion
- Subject has no contraindication to chemotherapy, and has no obvious obstacles in the function of major organs such as heart, lung, liver and kidney;
- Subject has middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C ;
- Liver function child-pugh class A or B; Karnofsky (KPS) score \> 60 points;
- Subject could not accept surgical resection or refuse surgical operation;and who did not receive other treatment before operation.
- 18\~75 years old; ECOG PS score: 0-1 points; expected survival period is more than 3 months.
Exclusion
- Subject has contraindications to chemotherapy;
- Subject has obstacle in the function of major organs such as heart, lung, liver and kidney;
- Severe coagulation dysfunction (prothrombin time \> 18 s or hemorrhagic tendency);
- Uncontrollable hypertension and portal hypertension;
- Hepatic artery-portal vein or hepatic vein fistula or portal vein trunk cancer thrombus;
- A large amount of ascites or refractory ascites;
- With distant metastasis.
Key Trial Info
Start Date :
August 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04066543
Start Date
August 30 2019
End Date
October 30 2021
Last Update
August 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China